Abstracts Archive - Page 1379 of 2607 - ACR Meeting Abstracts

Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 2894 • 2018 ACR/ARHP Annual Meeting
Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Juanita Romero-Díaz⁷, Jorge Sanchez-Guerrero⁴, Sasha Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Joan T. Merrill¹³, Paul R. Fortin¹⁴, Dafna D Gladman¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen M. Ginzler¹⁸, Mary Dooley¹⁹, Kristján Steinsson²⁰, Rosalind Ramsey-Goldman²¹, Asad A Zoma²², Susan Manzi²³, Ola Nived²⁴, Andreas Jönsen²⁴, Munther A Khamashta²⁵, Graciela S. Alarcón²⁶, Ronald F van Vollenhoven²⁷, Cynthia Aranow²⁸, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, Manuel Ramos-Casals³⁰, S. Sam Lim³¹, Murat Inanc³², Kenneth C. Kalunian³³, Søren Jacobsen³⁴, Christine A. Peschken³⁵, Diane L. Kamen³⁶, Anca Askanase³⁷, Chris Theriault³⁸ and Vernon Farewell³⁹, ¹Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁸Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Rayne Institute, University College London, London, United Kingdom, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²⁰Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²¹FSM, Northwestern University, Chicago, IL, ²²Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ²⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²⁶University of Alabama at Birmingham, Birmingham, AL, ²⁷Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ²⁸The Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁴Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ³⁹Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Psychosis, one of the rarer neuropsychiatric (NP) events in lupus patients, features in both the ACR and Systemic Lupus International Collaborating Clinics (SLICC) classification…
Abstract Number: 2895 • 2018 ACR/ARHP Annual Meeting
Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
Sara K. Tedeschi¹, Cynthia Aranow², Diane L. Kamen³, Meryl S. LeBoff⁴, Betty Diamond² and Karen Costenbader⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Bone health in SLE is adversely affected by vitamin D deficiency, inflammatory cytokines including interferon (IFN)-α, and glucocorticoid use. We tested the hypothesis that…
Abstract Number: 2896 • 2018 ACR/ARHP Annual Meeting
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
April Jorge¹, Na Lu^2,3, Eric C. Sayre³, Hamid Tavakoli⁴, Natalie McCormick⁵, John M. Esdaile^3,6, Mary DeVera⁵, Hyon K. Choi¹ and J. Antonio Avina-Zubieta⁷, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE. Use of this medication has previously been associated with a substantial survival benefit among SLE…
Abstract Number: 2897 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy
Michelle Petri¹, Marwa Elkhalifa², Daniel Goldman¹, Laurence S Magder³ and Mandeep Singh⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ⁴Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy after 10 years or more of use is more frequent than previously appreciated. This led to new ophthalmology guidelines that changed…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 2899 • 2018 ACR/ARHP Annual Meeting
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Xavier M Teitsma¹, Johannes W. G. Jacobs², Arno N Concepcion³, Attila Pethö-Schramm⁴, Michelle EA Borm⁵, Jacob van Laar¹, Johannes W. J. Bijlsma⁶ and Floris PJG Lafeber¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Roche Nederland BV, Woerden, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 2901 • 2018 ACR/ARHP Annual Meeting
Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels
Yuko Okamoto¹, Nickie L. Seto², Mariana J. Kaplan², Ashley Visser¹, Jill M. Norris³, Kevin D. Deane¹, V. Michael Holers⁴ and M. Kristen Demoruelle¹, ¹Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, NIAMS/NIH, Bethesda, MD, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Our group previously demonstrated that anti-citrullinated (cit) protein antibodies (ACPA) in the sputum correlate with remnants of neutrophil extracellular traps (NETs) in RA-free subjects…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
Abstract Number: 2903 • 2018 ACR/ARHP Annual Meeting
Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Chamith Fonseka¹, Deepak Rao², Nikola Teslovich³, Ilya Korsunsky⁴, Susan Hannes⁵, Kamil Slowikowski¹, Michael Gurish⁶, Laura T. Donlin⁷, James A. Lederer⁸, Michael Weinblatt⁹, Elena Massarotti⁹, Jonathan Coblyn⁹, Simon Helfgott¹⁰, Derrick J. Todd¹¹, Vivian P. Bykerk¹², Elizabeth Karlson¹³, Joerg Ermann¹⁴, Yvonne C. Lee¹⁵, Michael Brenner¹⁶ and Soumya Raychaudhuri^1,17, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ⁴Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁶Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁷Program in Medical and Population Genetics, Broad Institute, Boston, MA
Background/Purpose: Defining the precise CD4+ T cell subsets that are dysregulated in RA patients is critical to deciphering pathogenesis. Here we present Mixed effects modeling…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 2905 • 2018 ACR/ARHP Annual Meeting
Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
Berit Dalsgaard Nielsen¹, Ib Tønder Hansen², Kresten Krarup Keller³, Philip Therkildsen⁴, Lars Christian Gormsen⁵ and Ellen-Margrethe Hauge⁶, ¹Clnical Medicine, Department of Clinical Medicine, Aarhus University Hospital, Århus N, Denmark, ²Clinical Medicine, Department of Clinical Medicine, Aarhus University Hospital, Århus N, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ⁵Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark
Background/Purpose: EULAR recommendations suggest diagnostic imaging in all GCA suspects. Vascular ultrasound (US) is cheap, readily available and the recommended first line examination in cranial…
Abstract Number: 2906 • 2018 ACR/ARHP Annual Meeting
Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy
Daniel Kuo¹, Gurjit Kaeley², Ami Ben-Artzi³, Jenny Brook⁴, Astrid Floegel-Shetty⁴, David Elashoff⁴ and Veena K. Ranganath¹, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Rheumatology, Cedars Sinai Medical Center, Beverly Hills, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound is increasingly being used as a tool to assess inflammatory burden in rheumatoid arthritis (RA). Ultrasound-based outcome measures include power Doppler (PD)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].